A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

NCT04452877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals